| ABBOTT PARK, Illinois and MECHELEN, Belgium, February 29, 2012 /PRNewswire/ -- Selective JAK1 inhibitor in Phase II clinical development for rheumatoid arthritis Abbott to retain exclusive global commercial rights with Galapagos co-promotion in Benelux countries Galapagos to receive upfront payment of $150 million, with the potential for significant milestone payments Galapagos to host webcast presentation today at 4 p.m. CET/10 a.m. Eastern Abbott (NYSE: ABT) and Galapagos ...continued ABT GLPYY Healthcare Cosmetics laptop |
Wednesday, February 29, 2012
Abbott and Galapagos Announce Global Collaboration for Novel Oral Therapy, GLPG0634, in Phase II to Treat Autoimmune Diseases
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment